CAM
STSA

Cormorant Asset Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Cormorant Asset Management’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-798,905
Closed -$23M – 97
2020
Q2 		$23M Sell
798,905
-9,477
-1% -$219K 0.88% 37
2020
Q1 		$17.4M Sell
808,382
-50,000
-6% -$1.13M 0.81% 38
2019
Q4 		$16.9M Hold
858,382
– – 0.67% 40
2019
Q3 		$12.9M Buy
+858,382
New +$13.3M 0.78% 38

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Cormorant Asset Management's STSA Position: Q3 2020 in Review

Cormorant Asset Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2020, closing a stake of 798,905 shares — an estimated $23M sold.

Cormorant Asset Management first reported a position in STSA in Q3 2019 and held it in 4 quarters. The position peaked at $23M in Q2 2020. 46 funds tracked by Wall St. Rank hold STSA as of Q3 2020.

  • Cormorant Asset Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Cormorant Asset Management sold 798,905 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $23M.
  • Cormorant Asset Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • Cormorant Asset Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $23M in Q2 2020.
  • 46 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Cormorant Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.